Theratechnologies Inc. (THTX)
| Market Cap | 147.41M |
| Revenue (ttm) | 84.38M |
| Net Income (ttm) | -9.16M |
| Shares Out | 45.98M |
| EPS (ttm) | -0.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 3.390 |
| Day's Range | n/a |
| 52-Week Range | 1.120 - 3.420 |
| Beta | 0.81 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Oct 8, 2025 |
About THTX
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its product pipeline includes tesamorelin... [Read more]
Financial Performance
In 2024, Theratechnologies's revenue was $85.87 million, an increase of 5.02% compared to the previous year's $81.76 million. Losses were -$8.31 million, -65.33% less than in 2023.
Financial StatementsNews
SUMMER ROAD LLC Acquires Significant Stake in Theratechnologies Inc
SUMMER ROAD LLC Acquires Significant Stake in Theratechnologies Inc
Theratechnologies Announces Completion of Acquisition by Future Pak
MONTREAL, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today the c...
Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak
MONTREAL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that ...
Theratechnologies (THTX) Shareholders Approve Key Arrangement with CB Biotechnology
Theratechnologies (THTX) Shareholders Approve Key Arrangement with CB Biotechnology
Theratechnologies Inc. (TH:CA) Special Meeting Of Shareholders Of Theratechnologies Call (Transcript)
Theratechnologies Inc. (TSX:TH:CA) Special Meeting of Shareholders of Theratechnologies Call Company Participants Frank Holler - Chair of the Board Philippe Dubuc - Senior VP & CFO Presentation Opera...
Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak
MONTREAL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announc...
Theratechnologies (THTX) Launches New EGRIFTA WR Formulation for HIV Patients
Theratechnologies (THTX) Launches New EGRIFTA WR Formulation for HIV Patients
Theratechnologies Announces Availability of EGRIFTA WR⢠(tesamorelin) for injection to Reduce ...
Theratechnologies Announces Availability of EGRIFTA WR⢠(tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy | THTX Stock News
Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy
EGRIFTA WR™ offers convenience of weekly reconstitution and reduced daily injection volume, compared to EGRIFTA SV ®
Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future Pak
MONTREAL, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announc...
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
MONTREAL, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) announced today that it has filed and is in the process of mailing th...
Theratechnologies reports Q2 results
Theratechnologies Reports Financial Results for the Second Quarter 2025
MONTREAL, July 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today reported busines...
Earnings Scheduled For July 9, 2025
Companies Reporting Before The Bell • Target Hospitality (NASDAQ: TH) is projected to report quarterly earnings at $0.00 per share on revenue of $24.30 million. • Theratechnologies (NASDAQ: THTX) is...
A Look at Theratechnologies's Upcoming Earnings Report
Theratechnologies (NASDAQ: THTX) is gearing up to announce its quarterly earnings on Wednesday, 2025-07-09. Here's a quick overview of what investors should know before the release. Analysts are esti...
Theratechnologies to Announce Second Quarter 2025 Financial Results
MONTREAL, July 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced the Co...
Theratechnologies to be bought by CB Biotechnology for $254M
Theratechnologies enters into Definitive Agreement to be Acquired by CBÂ Biotechnology, an ...
Theratechnologies enters into Definitive Agreement to be Acquired by CBÂ Biotechnology, an Affiliate of Future Pak | THTX Stock News
Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak
MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that i...
Theratechnologies Reports on its Annual Meeting of Shareholders
MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, reported the voting res...
Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV
VAMOS analysis highlights link between EVAF and reduced muscle quality Case series reports success with combination tesamorelin/GLP-1 receptor agonist therapy MONTREAL, May 02, 2025 (GLOBE NEWSWIRE) -...
Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer
Theratechnologies is likely to accept Future Pak's $255 million offer, presenting a 39%-78% premium over current share prices, despite non-binding risks.
Theratechnologies to further evaluate potential sale of company
Theratechnologies Provides Update on Sale Process
MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that ...
Theratechnologies (THTX) Urged to Consider Acquisition Offer by Soleus Capital | THTX Stock News
Theratechnologies (THTX) Urged to Consider Acquisition Offer by Soleus Capital | THTX Stock News